Galderma Research & Development

Galderma S.a.

Galderma Holding Sa

Galderma Laboratories Inc.

Nestle Skin Health Sa

André Jomard

Laurence Clary

Jean-Guy Boiteau

Claire Bouix-Peter

Michel Rivier

Pascal Collette

Emmanuel Vial

Johannes Voegel

Jean Jacovella

Olivier Roye

Carine Rosignoli

Sandrine Rethore

Feriel Hacini-Rachinel

Laurent Fredon

Gérard Feraille

Françoise Delamadeleine

The present invention relates to a pharmaceutical composition comprising a compound of the avermectin family, preferably ivermectin, in a pharmaceutically acceptable carrier, for use in the treatment and/or prevention of hand eczema.

Compositions comprising a compound of the avermectin family for the treatment and/or prevention of hand eczema

The present invention relates to a composition comprising a pharmaceutically acceptable carrier, at least one compound of the avermectin family, and at least one non-steroidal anti-inflammatory compound. The present invention further provides such composition for use in the treatment and/or the prevention of rosacea.

Compositions and the use thereof for treating or preventing rosacea

A method of treating and/or preventing atopic dermatitis is described. The method includes use of a compound of the avermectin family, possibly ivermectin, or a compound of the milbemycin family in a pharmaceutically acceptable carrier.

Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis

Compounds or salts thereof are described that correspond to general formula (I) below: Also described, are pharmaceutical and cosmetic compositions that include these compounds. Methods of using these compounds and compositions for the treatment of pathological conditions are also described.

Selective compounds inhibiting CYP26A1 useful in cosmetic and pharmaceutical compositions

Methods and compositions for improved treatment and prevention of an inflammatory skin disorder or a sign and/or symptom associated with the skin disorder are described. The methods involve topical application to the skin a combination of a therapeutically effective amount of an &#x3b1;2 adrenergic receptor agonist, such as brimonidine, and a therapeutically effective amount of a non-steroidal anti-inflammatory agent, such as diclofenac.

Combination therapy for treating or preventing an inflammatory skin disorder

Travoprost medicament compositions for non-daily topical application are useful for simulating or inducing the growth and/or decreasing the loss and/or increasing the density and/or reducing the heterogeneity in the diameter of human hair shafts/follicles, e.g., for the treatment of androgenic alopecia, such medicament compositions being at least twice applied over a time interval of greater than 24 hours.

Topical application of travoprost for combating hair loss

A combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea is described. The combination of a compound of the avermectin family or of the mylbemycin family with a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists is also described. In addition, a product in the form of a kit including: (a) a first composition containing a compound of the avermectin family or of the mylbemycin family, and (b) a second composition different from the first one and containing a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists, as a combination product to be used as a drug for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay is described.

Combination of compounds for treating or preventing skin diseases

Growing community of inventors

Saint Vallier de Thiey, France

André Jomard